Dung Le
SKCCC Johns Hopkins Medical Institution · Johns Hopkins Medical Institution · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
15
all conditions, ClinicalTrials.gov
NIH grants tied to them
3
3 more share only the name and are not shown
Trial papers
71
PubMed author-name match
Trials
Studies that name Dung Le as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:04 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04753879 · Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Pancreatic Cancer · principal investigator
- Ph2NCT04177810 · Plerixafor and Cemiplimab in Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Pancreatic Cancer · principal investigator
- Ph2NCT04098068 · Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · High Tumor Mutation Burden, High TMB (Tumor Mutation Burden), MSS (Microsatellite Stable) · principal investigator
- Ph2NCT03642067 · Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma · principal investigator
- Ph2NCT03607890 · Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors · principal investigator
- Ph1/Ph2NCT03535727 · A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular · principal investigator
- Ph2NCT03190265 · Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Pancreatic Cancer · principal investigator
- Ph2NCT03006302 · Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Pancreatic Adenocarcinoma · principal investigator
- Ph1/Ph2NCT02324543 · Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Pancreatic Adenocarcinoma · principal investigator
- Ph2NCT02243371 · GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without NivolumabSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Previously Treated Metastatic Adenocarcinoma of the Pancreas · principal investigator
- Ph1NCT02048384 · A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Pancreatic Adenocarcinoma · study chair
- Ph2NCT01896869 · FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Pancreatic Adenocarcinoma · principal investigator
- Ph2NCT01876511 · Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers · principal investigator
- Ph2NCT01459614 · Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Pancreatic Cancer · principal investigator
- Ph1NCT00836407 · Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Pancreatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunityP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2021 to 2025 · $669,436 awarded in 2025Grant number is on one of their registry trials
- Phase 2 Study of Folfirinox Followed by Ipilimumab/GVAX in Pancreatic CancerR01FD004819 · FDA · JOHNS HOPKINS UNIVERSITY · fiscal years 2014 to 2017 · $400,000 awarded in 2017Same name and institution; not confirmed by an ID
- Cyclophosphamide modified GM-CSF pancreatic tumor vaccine + listeria-mesothelinK23CA163672 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2012 to 2015 · $178,739 awarded in 2015Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI Alison P Klein · fiscal years 1993 to 2022Named on NCT03607890
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:04 UTC. The ranking covers the 200 most relevant of 71 PubMed records, and a shared surname and initials can bring in a namesake. All 71 on PubMed
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.N Engl J Med · 20157,784 citationsRCR 243.1
- 5,520 citationsRCR 184.9
- Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.N Engl J Med · 20202,523 citationsRCR 109.5
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.J Clin Oncol · 20202,449 citationsRCR 111.1
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.Lancet Oncol · 20161,060 citationsRCR 32.1
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.Lancet Oncol · 2016909 citationsRCR 28.3
- Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans.Am J Clin Nutr · 2011884 citationsRCR 26.8
- 834 citationsRCR 57.3
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.J Clin Oncol · 2020810 citationsRCR 32.3
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.Lancet Oncol · 2016547 citationsRCR 16.4